Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...

GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr.

Novavax is a biotechnology company specializing in the development of recombinant protein-based vaccines, including its COVID-19 shot and the adjuvant Matrix-M, which enhances immune responses. Its ...

Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical Officer Dr. Walker will continue advancing Novavax's R&D efforts with ...

Jan 20 (Reuters) - Novavax ‌said on Tuesday it signed a licensing ‌agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, ...

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Novavax is a biotechnology company specializing in the ...

Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

Good morning, and welcome to the Novavax First Quarter 2026 Financial Results and Operational Highlights Conference Call. [Operator Instructions] Please note, this event is being recorded. It is now ...

Investors with a lot of money to spend have taken a bearish stance on Novavax NVAX. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...